✦ LIBER ✦

Weekly 1-hour infusion of paclitaxel : Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma

✍ Scribed by Charu Trivedi; Bruce Redman; Lawrence E. Flaherty; Omer Kucuk; Wei Du; Lance K. Heilbrun; Maha Hussain

Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 85 KB
Volume: 89
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(20000715)89:2<431::aid-cncr31>3.0.co;2-b

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase I/II study of weekly paclitaxel

A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma

✍ Anna C. Ferrari; Abraham Chachoua; Harvinder Singh; Mark Rosenthal; Samir Taneja 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 1 views

Phase I/II trial of paclitaxel by 1-hour

Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma

✍ John D. Hainsworth; Howard A. Burris III; Joan B. Erland; Lisa H. Morrissey; Ant 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 2 views

## BACKGROUND. The combination of paclitaxel and carboplatin is widely used in the treatment of patients with advanced nonsmall cell lung carcinoma. In this Phase I/II study the authors evaluated the feasibility, toxicity, and efficacy of adding a third active antineoplastic agent, gemcitabine, to